Taysha Gene Therapies Inc
NASDAQ:TSHA

Watchlist Manager
Taysha Gene Therapies Inc Logo
Taysha Gene Therapies Inc
NASDAQ:TSHA
Watchlist
Price: 1.72 USD Market Closed
Market Cap: 352.6m USD

Taysha Gene Therapies Inc
Investor Relations

Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas and currently employs 178 full-time employees. The company went IPO on 2020-09-24. The firm is focused on developing and commercializing adeno-associated virus (AAV)-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). Its portfolio of gene therapy candidates targets a range of neurological indications across three distinct therapeutic categories: neurodegenerative diseases, neurodevelopmental disorders and genetic epilepsies. Its product candidates include TSHA-101, which is being developed for the treatment of giant axonal neuropathy (GAN); TSHA-102, a neurodevelopmental disorder product candidate, which is being developed for the treatment of Rett syndrome; TSHA-118, which is a AAV9 viral vector that expresses human codon-optimized Ceroid Lipofuscinosis Neuronal 1 complementary deoxyribonucleic acid under control of the chicken b-actin hybrid promoter, and TSHA-105, a gene replacement therapy for the treatment of SLC13A5 deficiency.

Show more
Loading

Earnings Calls

2024 Q3
Nov 13, 2024
Show Transcript
Previous
Next
Taysha Gene Therapies Progress in Rett Syndrome Treatment
2024 Q3
Nov 13, 2024

In Q3 2024, Taysha Gene Therapies made significant strides in its TSHA-102 program for Rett syndrome, emphasizing regulatory advancements with the FDA. During this period, they enrolled additional patients in pivotal high-dose trials, showing encouraging safety and efficacy data. Notably, the company anticipates reporting longer-term data from both low and high-dose cohorts in early 2025. As of September 30, 2024, Taysha holds $157.7 million in cash, sufficient to support operations until Q4 2026. The management maintains confidence in TSHA-102’s potential to enhance patient quality of life and aims to expedite the journey toward regulatory approvals.

Show Full Analysis

Management

Mr. Sean P. Nolan
CEO & Chairman
No Bio Available
Dr. Sukumar Nagendran M.D.
President, Head of Research & Development and Director
No Bio Available
Mr. Kamran Alam CPA, M.B.A.
CFO & Corporate Secretary
No Bio Available
Hayleigh Collins
Director of Corporate Communications & Investor Relations
No Bio Available
Ms. Tracy M. Porter SPHR
Chief People Officer
No Bio Available
Mr. Frederick Porter Ph.D.
Chief of Staff & Technical Operations Officer
No Bio Available
Ms. Emily McGinnis M.P.H.
Chief Patient & External Affairs Officer and Endpoint & Outcome Development Lead
No Bio Available
Mr. Sean McAuliffe
Chief Business Officer
No Bio Available
Dr. Steven Gray Ph.D.
Chief Scientific Advisor of UT Southwestern Gene Therapy Program
No Bio Available
Berge Minassian M.D.
Chief Medical Advisor of UT Southwestern Gene Therapy Program
No Bio Available

Contacts

Address
TEXAS
Dallas
3000 Pegasus Park Drive, Suite 1430
Contacts
+12146120000.0
tayshagtx.com